TRDNT Challenge Phase II: Prototype Development and Use Case Demonstration
Pays up to $120,000 per Interim Milestone winner and up to $320,000 per Final Submission winner to US-based researchers, startups and institutions that build a working prototype technology able to target endogenous RNA in human disease.
About
In this phase, participants design an initial prototype RNA-targeting technology, provide an example use case against a disease-relevant RNA target, and lay out a public access and dissemination plan for the eventual technology. Interim Milestone submissions are judged first, with up to 25 winners paid up to $120,000 each; only those interim winners can then submit a Final Submission, where up to …
BiotechMedtech
Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.